PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Novel compound halts tumor spread, improves brain cancer treatment in animal studies

Novel compound halts tumor spread, improves brain cancer treatment in animal studies
2012-03-29
(Press-News.org) Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

To address this challenge, researchers from the Georgia Institute of Technology and Emory University have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models. The researchers treated animals possessing an invasive tumor with a vesicle carrying a molecule called imipramine blue, followed by conventional doxorubicin chemotherapy. The tumors ceased their invasion of healthy tissue and the animals survived longer than animals treated with chemotherapy alone.

"Our results show that imipramine blue stops tumor invasion into healthy tissue and enhances the efficacy of chemotherapy, which suggests that chemotherapy may be more effective when the target is stationary," said Ravi Bellamkonda, a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. "These results reveal a new strategy for treating brain cancer that could improve clinical outcomes."

The results of this work were published on March 28, 2012 in the journal Science Translational Medicine. The research was supported primarily by the Ian's Friends Foundation and partially by the Georgia Cancer Coalition, the Wallace H. Coulter Foundation and a National Science Foundation graduate research fellowship.

In addition to Bellamkonda, collaborators on the project include Jack Arbiser, a professor in the Emory University Department of Dermatology; Daniel Brat, a professor in the Emory University Department of Pathology and Laboratory Medicine; and the paper's lead author, Jennifer Munson, a former Fulbright Scholar who was a bioengineering graduate student in the Georgia Tech School of Chemical & Biomolecular Engineering when the research was conducted.

Arbiser designed the novel imipramine blue compound, which is an organic triphenylmethane dye. After in vitro experiments showed that imipramine blue effectively inhibited movement of several cancer cell lines, the researchers tested the compound in an animal model of aggressive cancer that exhibited attributes similar to a human brain tumor called glioblastoma.

"There were many reasons why we chose to use the RT2 astrocytoma rat model for these experiments," said Brat. "The tumor exhibited properties of aggressive growth, invasiveness, angiogenesis and necrosis that are similar to human glioblastoma; the model utilized an intact immune system, which is seen in the human disease; and the model enabled increased visualization by MRI because it was a rat model, rather than a mouse."

Because imipramine blue is hydrophobic and doxorubicin is cytotoxic, the researchers encapsulated each compound in an artificially-prepared vesicle called a liposome so that the drugs would reach the brain. The liposomal drug delivery vehicle also ensured that the drugs would not be released into tissue until they passed through leaky blood vessel walls, which are only present where a tumor is growing.

Animals received one of the following four treatments: liposomes filled with saline, liposomes filled with imipramine blue, liposomes filled with doxorubicin chemotherapy, or liposomes filled with imipramine blue followed by liposomes filled with doxorubicin chemotherapy.

All of the animals that received the sequential treatment of imipramine blue followed by doxorubicin chemotherapy survived for 200 days -- more than 6 months -- with no observable tumor mass. Of the animals treated with doxorubicin chemotherapy alone, 33 percent were alive after 200 days with a median survival time of 44 days. Animals that received capsules filled with saline or imipramine blue – but no chemotherapy -- did not survive more than 19 days.

"Our results show that the increased effectiveness of the chemotherapy treatment is not because of a synergistic toxicity between imipramine blue and doxorubicin. Imipramine blue is not making the doxorubicin more toxic, it's simply stopping the movement of the cancer cells and containing the cancer so that the chemotherapy can do a better job," explained Bellamkonda, who is also the Carol Ann and David D. Flanagan Chair in Biomedical Engineering and a Georgia Cancer Coalition Distinguished Cancer Scholar.

MRI results showed a reduction and compaction of the tumor in animals treated with imipramine blue followed by doxorubicin chemotherapy, while animals treated with chemotherapy alone presented with abnormal tissue and glioma cells. MRI also indicated that the blood-brain barrier breach often seen during tumor growth was present in the animals treated with chemotherapy alone, but not the group treated with chemotherapy and imipramine blue.

According to the researchers, imipramine blue appears to improve the outcome of brain cancer treatment by altering the regulation of actin, a protein found in all eukaryotic cells. Actin mediates a variety of essential biological functions, including the production of reactive oxygen species. Most cancer cells exhibit overproduction of reactive oxygen species, which are thought to stimulate cancer cells to invade healthy tissue. The dye's reorganization of the actin cytoskeleton is thought to inhibit production of enzymes that produce reactive oxygen species.

"I formulated the imipramine blue compound as a triphenylmethane dye because I knew that another triphenylmethane dye, gentian violet, exhibited anti-cancer properties, and I decided to use imipramine -- a drug used to treat depression -- as the starting material because I knew it could get into the brain," said Arbiser.

For future studies, the researchers are planning to test imipramine blue's effect on animal models with invasive brain tumors, metastatic tumors, and other types of cancer such as prostate and breast.

"While we need to conduct future studies to determine if the effect of imipramine blue is the same for different types of cancer diagnosed at different stages, this initial study shows the possibility that imipramine blue may be useful as soon as any tumor is diagnosed, before anti-cancer treatment begins, to create a more treatable tumor and enhance clinical outcome," noted Bellamkonda.



INFORMATION:


[Attachments] See images for this press release:
Novel compound halts tumor spread, improves brain cancer treatment in animal studies

ELSE PRESS RELEASES FROM THIS DATE:

Nowspeed Releases Mobile Marketing White Paper

2012-03-29
Nowspeed, a top Internet marketing agency, has released a new mobile marketing white paper entitled, 25 Reasons You Need a Mobile Marketing Strategy Today, co-written by Account Director of Nowspeed, Olivier Sartor and Creative Director of Nowspeed, Justin Barton. The white paper explains how and why it is important for companies to incorporate a mobile business strategy in today's marketing space. Businesses will learn the efficiencies of mobile marketing through 25 tips and best practices that will jumpstart your efforts to create a mobile marketing strategy that works. ...

Fossil raindrop impressions imply greenhouse gases loaded early atmosphere

Fossil raindrop impressions imply greenhouse gases loaded early atmosphere
2012-03-29
In ancient Earth history, the sun burned as much as 30 percent dimmer than it does now. Theoretically that should have encased the planet in ice, but there is geologic evidence for rivers and ocean sediments between 2 billion and 4 billion years ago. Scientists have speculated that temperatures warm enough to maintain liquid water were the result of a much thicker atmosphere, high concentrations of greenhouse gases or a combination of the two. Now University of Washington researchers, using evidence from fossilized raindrop impressions from 2.7 billion years ago ...

Revision Rhinoplasty

2012-03-29
There are several reasons a person might consider rhinoplasty. Perhaps your nose is misshapen, or not the right size for your face. Perhaps your nose distracts from your natural beauty, or makes your face look asymmetrical or unappealing. In any case, the decision to have rhinoplasty is a big one. Unfortunately, many people experience uneven, displeasing results after rhinoplasty. Revision Rhinoplasty When your nose job fails to provide you with an appealing end result, you may want to consider revision rhinoplasty. With revision rhinoplasty, your plastic surgeon ...

Many billions of rocky planets in the habitable zones around red dwarfs in the Milky Way

Many billions of rocky planets in the habitable zones around red dwarfs in the Milky Way
2012-03-29
This first direct estimate of the number of light planets around red dwarf stars has just been announced by an international team using observations with the HARPS spectrograph on the 3.6-metre telescope at ESO's La Silla Observatory in Chile [1]. A recent announcement (eso1204 - http://www.eso.org/public/news/eso1204/), showing that planets are ubiquitous in our galaxy used a different method that was not sensitive to this important class of exoplanets. The HARPS team has been searching for exoplanets orbiting the most common kind of star in the Milky Way — red dwarf ...

Choosing an Auto Accident Lawyer

2012-03-29
If you have been seriously hurt in an auto accident, you may be trying to decide whether you need a lawyer. And once you have decided that you do need a lawyer, how do you find the right one for you? Here are some pieces of advice that can help you find the right lawyer. Look for Personal Recommendations Do you know friends or family members who have gone through an auto accident lawsuit? If so, then ask them about their experience and whether they would recommend their lawyer. If they recommend their lawyer, add him or her to your list. If you see your doctor ...

Stopping statin therapy increases risk of death for rheumatoid arthritis patients

2012-03-29
Patients with rheumatoid arthritis (RA) who discontinue use of statin therapy are at increased risk of death from cardiovascular disease and other causes. According to the findings of a population-based study now available in Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), RA patients should be advised of the importance of compliance to their statin therapy to reduce cardiovascular disease (CVD) mortality risk. A report from the World Health Organization (WHO) estimates that RA affects up to one ...

Researchers identify new regulator in allergic diseases

2012-03-29
CINCINNATI - Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13). Scientists from Cincinnati Children's Hospital Medical Center say the finding opens the potential for new molecular targets to treat allergic disease. They report on March 28 in Mucosal Immunology that a particular microRNA, miR-375, is regulated by IL-13, and in turns regulates how IL-13 induces pro-allergic changes, particularly in epithelial cells in the lung and esophagus. The ...

Novartis launches the Cancer Cell Line Encyclopedia to catalog world's cancer cell lines

2012-03-29
Collaboration with the Broad Institute yields comprehensive encyclopedia of genetic and molecular information for nearly 1,000 cancer cell lines Encyclopedia, publicly available, may improve the design of cancer trials and advance cancer research Data from encyclopedia may help researchers identify patients who could most benefit from any given drug Basel, March 28, 2012 – Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research ...

What Can Cosmetic Dentistry Fix?

2012-03-29
Many people have some aspect of their smile they would like to improve. With cosmetic dentistry, you can achieve a beautiful, healthy smile you can share confidently. If you have a tendency to hide your smile from other people, you should consult a cosmetic dentist about possible smile improvements. Your smile should let you express your innermost feelings and emotions, and cosmetic dentistry may be a good way for you to create a smile that truly feels like your own. Common Cosmetic Dental Problems Some of the most common cosmetic dentistry issues include: - Crooked ...

Taking some time off can help when learning a new language

2012-03-29
When learning a new language, it doesn't hurt to take a break, according to surprising new research published Mar. 28 in the open access journal PLoS ONE. Adult subjects who had been taught to speak and comprehend an artificial language to high proficiency and then went several months without any further exposure did not show any change in their language abilities after the time off, report the authors, led by Michael Ullman of Georgetown University in Washington, D.C. and Kara Morgan-Short of the University of Illinois at Chicago. The time away from the language ...

LAST 30 PRESS RELEASES:

McGill discovery sheds new light on autism, intellectual disabilities

Cellular changes occur even below the hexavalent chromium limit

Study suggests a new way to curb social media’s body image toll

Plant doctor: An AI system that watches over urban trees without touching a leaf

Study tracks chromium chemistry in irradiated molten salts

Scientists: the beautiful game is a silver bullet for global health

Being physically active, even just a couple of days a week, may be key to better health

High-fat diet promote breast cancer metastasis in animal models

A router for photons

Nurses and AI collaborate to save lives, reduce hospital stays

Multi-resistance in bacteria predicted by AI model

Tinker Tots: A citizen science project to explore ethical dilemmas in embryo selection

Sensing sickness

Cost to build multifamily housing in California more than twice as high as in Texas

Program takes aim at drinking, unsafe sex, and sexual assault on college campuses

Inability to pay for healthcare reaches record high in U.S.

Science ‘storytelling’ urgently needed amid climate and biodiversity crisis

KAIST Develops Retinal Therapy to Restore Lost Vision​

Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response

Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid

Low LDL cholesterol levels linked to reduced risk of dementia

Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients

Almost one in ten people surveyed report having been harmed by the NHS in the last three years

Enhancing light control with complex frequency excitations

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

New insight into factors associated with a common disease among dogs and humans

Illuminating single atoms for sustainable propylene production

New study finds Rocky Mountain snow contamination

Study examines lactation in critically ill patients

UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award

[Press-News.org] Novel compound halts tumor spread, improves brain cancer treatment in animal studies